Guess which All Ords ASX healthcare stock just surged 11% on FDA news

Investors are sending the ASX healthcare stock soaring on Monday.

The All Ordinaries Index (ASX: XAO) is up 0.4% in late morning trade on Monday, with one ASX healthcare stock doing plenty of the heavy lifting.

The high-flying company in question is Silicon Valley-based EBR Systems Inc (ASX: EBR), which is focused on treating cardiac rhythm disease.

EBR Systems shares closed on Friday trading at $1.365. At the time of writing, they are 7.8% higher at $1.47 after leaping to an intraday high of $1.52, up 11.4%.

As you can see on the chart below, that sees the ASX healthcare stock up a very, well, healthy 138% over the past 12 months.

Here's what's spurring investor interest today.

Two lab workers fist pump each other.

Image source: Getty Images

ASX healthcare stock leaps on FDA update

Investors are bidding up the EBR Systems share price after the company, developing the world's only wireless cardiac pacing device for heart failure (WiSE System), announced that the US Food and Drug Administration (FDA) has scheduled the manufacturing Pre-Approval Inspection (PAI) to commence next week, on 14 January.

The ASX healthcare stock had previously anticipated that the PAI would start this week. However, management noted that the one-week delay won't impact the expected FDA regulatory approval timing, which was said to remain on track for the first quarter of calendar year 2025.

Commercial launch is then projected to take place later this year.

According to the release, the PAI's purpose is to confirm that EBR's manufacturing procedures comply with US quality system regulations and ensure that EBR can consistently produce devices that meet these approved specifications.

EBR reiterated that the FDA has previously said that the onsite Biomedical Monitoring (BIMO) audit is unlikely to be a requirement prior to final approval.

The Breakthrough Device designation for the WiSE System enables EBR to receive prioritised review and interactive communication with the FDA until the review process is completed.

The ASX healthcare stock initially released details of the FDA's review process on 30 September.

At the time, EBR Systems CEO John McCutcheon said:

We are delighted that our PMA application has progressed to substantive review by the FDA, effectively moving into the final stages of our regulatory timeline. The FDA moved quickly through this step, which could have taken up to 45 days.

This significant milestone brings us even closer to US commercialisation and to making available our life-changing WiSE technology to heart failure patients in need.

That announcement came shortly after the ASX healthcare stock secured $50 million in new funding. The company noted this provided it with a "cash runway" to get it through the FDA approval process, adding that the funds would also support it through early commercialisation and revenue growth.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »